In October 2023, the EC approved Enhertu for treating advanced non-small cell lung cancer patients with a HER2 mutation.

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

In the DESTINY-Breast03 trial, Enhertu (trastuzumab deruxtecan ... the DESTINY-Lung01 study in HER2-positive non-small cell lung cancer (NSCLC), including an overall response rate of 55% and ...

ENHERTU is a specifically engineered HER2 directed ... adjuvant chemotherapy Unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

In October 2023, the EC approved Enhertu for treating advanced non-small cell lung cancer patients with a HER2 mutation. "Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...